We are seeking a highly motivated individual to undertake a PhD in the health economics of prostate cancer.
The Centre for Health Economics Research and Evaluation (CHERE) is collaborating with the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) on the international project: Intermediate Clinical Endpoints for Cancer of the Prostate (ICECaP). ICECaP is using data from more than 28,900 prostate cancer patients to test and validate an intermediate clinical outcome for use as a surrogate for overall survival in men with prostate cancer.
Two of the objectives of ICECaP are:
(1) to assess the implications of the use of a proposed surrogate outcome measure for determining the cost-effectiveness of treatments for men with prostate cancer; and
(2) to determine the value associated with the use of a surrogate outcome as the basis for registration and reimbursement compared with delaying market entry by waiting for mature overall survival data in a clinical trial setting.
This PhD will address these two objectives, using Australia as the reference country upon which to build an analysis of international significance.
This PhD offers a full-time scholarship (up to $35,000 per annum) for three 3 years. There is also the potential for top-up funding and travel support for meeting attendance as part of this program. To be considered for eligibility, candidates should complete the expression of interest and meet the following minimum requirements:
The successful candidate will enrol at the University of Technology Sydney and commence studies by the PhD census date for the autumn intake of 2019.
Interested candidates should contact Richard De Abreu Lourenco (email@example.com or
+61(0)2 9514 4729) at CHERE for more information and to request a submission pack.
Applications close 30th September 2018.
For more information on CHERE please visit: www.chere.uts.edu.au
For more information on ANZUP please visit: www.anzup.org.au